However, subsequent injection of YS-49 improved the size and weight of RAD21-KD H1299 (Fig. 9a, b) or H1650 (Fig. 9c, d) tumors, suggesting that YS-49 reversed the inhibitory effect of RAD21 knockdown on NSCLC development in vivo. This evidence concerns the gene RAD21 and non-small cell lung carcinoma.